CME Corner

Program Detail

Release Date: February-28-19
Credit Expiration Date: February-28-20


Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Houston, TX

Reynold A. Panettieri, Jr., MD
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Robert Wood Johnson Medical School
Emeritus Professor of Medicine, University of Pennsylvania
Rutgers Institute for Translational Medicine and Science
New Brunswick, NJ

Credit Hours



Mobile + Online on RealCME

Program Description

This interactive case-based activity will examine factors contributing to severe asthma, the role of type 2 inflammation, and novel agents to manage severe asthma in patients with type 2 inflammation.

Program Developer/Facilitator


Target Audience

Pulmonologists, allergists, primary care physicians, NPs, PAs, and other clinicians who encounter patients with asthma.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the role of type 2 inflammation in asthma pathophysiology and the phenotypic and endotypic characterization of asthma with type 2 inflammation.
  2. Review the mechanism of action, efficacy, and safety of targeted agents approved for the management of severe, uncontrolled asthma with type 2 inflammation and those in late-stage development.
  3. Incorporate agents targeted at type 2 inflammation into the management of appropriate patients with severe, uncontrolled asthma not responding to ICS and bronchodilator therapy.


All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.

Dr. Hanania discloses the following:
Grants/research support: GSK, Boehringer-Ingelheim, AstraZeneca, Sanofi
Consultant: GSK, AstraZeneca, Sanofi, Novartis

Dr. Panettieri discloses the following:
Grants/research support: AstraZeneca, MedImmune, Research Institute of Fragrance Materials, OncoArendi, Equillium, Sienna Biopharmaceuticals
Consultant: AstraZeneca, MedImmune, Teva, Novartis, Boehringer-Ingelheim
Speakers bureau: AstraZeneca, MedImmune, Teva, Novartis, Boehringer-Ingelheim, Sanofi/Regeneron, Genentech
Advisory board: Equillium

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023554. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid for one year from 02/28/2019. PAs should only claim credit commensurate with the extent of their participation.

Commercial Support Statements

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Certificate Fee



2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu